This report evaluates the clinical utility for MTHFR pharmacogenomic genotyping in pediatric or adult patients to alter drug choice, drug dose, or otherwise mitigate drug treatment according to patient genotype in order to avoid adverse events, maintain adherence, and improve disease outcomes.
If you have a Hayes login, click here to view the full report on the Knowledge Center.